This is my archive
–Company Receives Five-year Exclusivity Extension Through GAIN Act — SAINT-LOUIS, France & WEILL AM RHEIN, Germany, February 27,2024 – Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® (cefepime/enmetazobactam), as a treatment for… Read More
Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in all territories except China. In China, Eccogene and AstraZeneca will partner for… Read More
PT886 is Phanes’ first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck’s anti-PD-1 The clinical trial collaboration will focus on evaluating PT886 in combination with KEYTRUDA® for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas PT886 is also being studied for the treatment of pancreatic cancer… Read More
October 9, 2023, San Diego and Shanghai – Sirius Therapeutics today announced that it has completed a US$60 million Series B financing to advance the clinical development of the Company’s novel siRNA therapeutics and the continued innovation of the next-generation RNA delivery technologies. This financing round was led by Hankang… Read More
Secured financing advances Instylla’s clinical trials and commercialization readiness BEDFORD, Mass., Aug. 15, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the closing of a $30 million financing round. This financing round was led by new investor, Delos Capital, with… Read More
– Proceeds to support the development of Eccogene’s clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders Boston/Shanghai/June 12nd, 2023 — Eccogene, Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic… Read More
Previously announced $85 million financing extended by $50 million BOSTON, May 16, 2023 – Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of… Read More
SAN DIEGO, March 6, 2023 /PRNewswire/ — Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company. The collaboration will leverage Phanes’ proprietary technology platforms, PACbody™ and… Read More
Proceeds to accelerate commercialization and pipeline expansion of novel FLASH™ Aorto-Ostial Angioplasty System CAMPBELL, Calif., Feb. 8, 2023 /PRNewswire/ — Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, today announced the raise of $7.5M in growth funding led by Delos… Read More
Funding will support development of lead assets and enhance target discovery and platform development CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos… Read More
